The FDA granted accelerated approval for Truvada, a fixed-dose combination of Gilead Sciences Inc.'s anti-HIV medications Emtriva and Viread. (BioWorld Today)

Gilead's Combination HIV Drug, Truvada, Wins FDA Clearance

Aug. 4, 2004

By Kim Coghill

The FDA granted accelerated approval for Truvada, a fixed-dose combination of Gilead Sciences Inc.'s anti-HIV medications Emtriva and Viread. (BioWorld Today)

Today's news in brief
BioWorld
BioWorld briefs for March 6, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...